Noema Pharma AG
6
0
2
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
25%
1 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome
Role: lead
A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus)
Role: lead
An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.
Role: lead
A Study of NOE-115 in Women With Vasomotor Symptoms Due to Menopause
Role: lead
Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC
Role: lead
A Study to Validate a Pain Diary for Patient With Trigeminal Neuralgia
Role: lead
All 6 trials loaded